202 related articles for article (PubMed ID: 17318418)
1. Antiangiogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular internality for cancer therapy.
Yu MK; Lee DY; Kim YS; Park K; Park SA; Son DH; Lee GY; Nam JH; Kim SY; Kim IS; Park RW; Byun Y
Pharm Res; 2007 Apr; 24(4):705-14. PubMed ID: 17318418
[TBL] [Abstract][Full Text] [Related]
2. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor.
Lee E; Kim YS; Bae SM; Kim SK; Jin S; Chung SW; Lee M; Moon HT; Jeon OC; Park RW; Kim IS; Byun Y; Kim SY
Int J Cancer; 2009 Jun; 124(12):2755-65. PubMed ID: 19243020
[TBL] [Abstract][Full Text] [Related]
3. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
4. Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth.
Park K; Kim YS; Lee GY; Park RW; Kim IS; Kim SY; Byun Y
Pharm Res; 2008 Dec; 25(12):2786-98. PubMed ID: 18581207
[TBL] [Abstract][Full Text] [Related]
5. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effect of bile acid acylated heparin derivative.
Park K; Kim YS; Lee GY; Nam JO; Lee SK; Park RW; Kim SY; Kim IS; Byun Y
Pharm Res; 2007 Jan; 24(1):176-85. PubMed ID: 17109210
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention.
Kim JY; Al-Hilal TA; Chung SW; Kim SY; Ryu GH; Son WC; Byun Y
J Control Release; 2015 Feb; 199():122-31. PubMed ID: 25523032
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic activity and antitumor efficacy of amphiphilic twin drug from ursolic acid and low molecular weight heparin.
Cheng W; Dahmani FZ; Zhang J; Xiong H; Wu Y; Yin L; Zhou J; Yao J
Nanotechnology; 2017 Feb; 28(7):075102. PubMed ID: 28091396
[TBL] [Abstract][Full Text] [Related]
11. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
12. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
13. An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties.
Bae SM; Kim JH; Chung SW; Byun Y; Kim SY; Lee BH; Kim IS; Park RW
Biomaterials; 2013 Mar; 34(8):2077-86. PubMed ID: 23245333
[TBL] [Abstract][Full Text] [Related]
14. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
[TBL] [Abstract][Full Text] [Related]
15. Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice.
Thorpe PE; Derbyshire EJ; Andrade SP; Press N; Knowles PP; King S; Watson GJ; Yang YC; Rao-Betté M
Cancer Res; 1993 Jul; 53(13):3000-7. PubMed ID: 7686447
[TBL] [Abstract][Full Text] [Related]
16. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.
Maffucci T; Piccolo E; Cumashi A; Iezzi M; Riley AM; Saiardi A; Godage HY; Rossi C; Broggini M; Iacobelli S; Potter BV; Innocenti P; Falasca M
Cancer Res; 2005 Sep; 65(18):8339-49. PubMed ID: 16166311
[TBL] [Abstract][Full Text] [Related]
18. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
20. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
